On May 18, the House Energy and Commerce Subcommittee on Health approved, by voice vote, the Food and Drug Administration (FDA) Reauthorization Act (H.R. 2430), as amended. The measure would reauthorize FDA’s authority to collect fees on prescription and generic drugs, medical devices, and biosimilar products.
The Senate Health, Education, Labor, and Pensions Committee passed its version of the bill, S. 934, on May 11 (see The Source, 5/12/17).
